ASCELIA – AN ONCOLOGY-DEDICATED DRUG DEVELOPMENT COMPANY

ADVANCING
ORPHAN ONCOLOGY

TO IMPROVE THE LIFE OF PEOPLE
LIVING WITH CANCER
BY OFFERING BETTER TREATMENT OPTIONS

OUR STORY

Our Vision

Our vision is to be a leader in identifying, developing and commercializing novel drugs that address unmet needs of people with rare cancer conditions.

Learn more about us:

Ascelia Pharma company presentation May 2022

Q1-2022 investor conference call

Quarterly Report Q1-2022

TOP STORIES

Ascelia Pharma Announces Successful Final Results from Orviglance Hepatic Impairment Study

2022-09-28 10:30:00

Ascelia Pharma AB (publ) (ticker: ACE), a biotech focused on improving the life of people living with rare cancer conditions, today announced the final results of the Hepatic Impairment Study confirmi …

TOP STORIES

Ascelia Pharma’s Food Effect Study shows that Orviglance image enhancement of the liver is not reduced by light meal

2022.04.11

Ascelia Pharma AB (publ) (ticker: ACE) today announced the results of the Food Effect Study that evaluated the effect of food intake on absorption and signal intensity of Orviglance®. The results show …

TOP STORIES

New market research shows strong support for Orviglance

2022.03.29

New independent market research shows that 84% of healthcare professionals will likely use Orviglance® for magnetic resonance imaging (MRI) in patients with cancer in the liver and reduced kidney function.

Read more about the results:

Market Research Presentation

Upcoming Events

Interim report 9M

Report will be released at 08:00am CET and conference call at 10:00am CET

Full-Year report 2022

Report will be released at 08:00am CET and conference call at 10:00am CET

View all events

Latest News

Ascelia Pharma expands its leadership team

Ascelia Pharma AB (publ) (ticker: ACE) a biotech focused on improving the life of people living with rare cancer conditions, today announced that it has expanded its leadership team to include all line functions that report directly to CEO Magnus Corfitzen. The company’s Chief Medical Officer (CMO) Carl Bjartmar has decided to retire by the [&helli …

Ascelia Pharma Announces Successful Final Results from Orviglance Hepatic Impairment Study

Ascelia Pharma AB (publ) (ticker: ACE), a biotech focused on improving the life of people living with rare cancer conditions, today announced the final results of the Hepatic Impairment Study confirming that the company’s lead drug candidate, the magnetic resonance imaging (MRI) contrast agent Orviglance®, is well tolerated in patients with hepatic …

Half-year report 2022: Strong results from Orviglance Food Effect Study

Ascelia Pharma AB (publ) (ticker: ACE) today published its half-year financial report for 2022 (January – June 2022), which is now available on the company’s website: https://www.ascelia.com/ir-media/financial-reports/

Presentations & Articles

ABGSC Investor Day

CEO Magnus Corfitzen presents at ABG Investor Day

HC Andersen – Oncology Seminar

Chief Executive Officer presents at HC Andersen Oncology Seminar

Erik Penser Bank – Company Day

Chief Executive Officer presents at Erik Pensers Company Day

INVESTOR

Shortcut to our latest Financial Reports

PEOPLE

Meet our CEO Magnus Corfitzen

Listen to Ascelia Pharma’s CEO Magnus Corfitzen and the vision and plans for the company